Printer Friendly

FDA REVIEW OF XOMA'S E5(R) PRODUCT IS ACTIVE; COMPANY BELIEVES MARKET OVERREACTED

 FDA REVIEW OF XOMA'S E5(R) PRODUCT IS ACTIVE;
 COMPANY BELIEVES MARKET OVERREACTED
 BERKELEY, Calif., April 15 /PRNewswire/ -- XOMA Corp. (NASDAQ-NMS: XOMA) yesterday re-affirmed that the company's E5(R) anti- endotoxin monoclonal antibody product is under active review by the Food and Drug Administration (FDA) for approval for the treatment of gram- negative sepsis.
 "Our announcement yesterday led to concerns in the market that a significant problem had arisen in the FDA's review of E5," said XOMA Chairman and Chief Executive Officer Steven C. Mendell. "Those concerns are unfounded; we think the market misunderstood the earlier announcement and overreacted to it."
 XOMA President Patrick J. Scannon, M.D., Ph.D., said, "We recently received notification from FDA that, on its own, the first of the two randomized clinical studies of our E5 product would not be sufficient for licensure of the product. However, this does not in any way imply a delay or setback in the agency's review of E5. In fact, we are encouraged by the progress FDA is making in its review. We have conducted two large clinical studies with E5 involving approximately 1,300 patients. When the two trials are combined, we believe the safety and effectiveness of E5 is clearly demonstrated," Scannon concluded.
 XOMA Corp. is a leading company in the development of therapeutic products using monoclonal antibody and recombinant DNA technologies.
 -0- 4/15/92
 /CONTACT: Carol D. DeGuzman of XOMA, 510-644-1170/
 (XOMA) CO: XOMA Corp. ST: California IN: MTC SU:


KJ-EH -- LA014 -- 8479 04/15/92 08:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 15, 1992
Words:255
Previous Article:PIONEER SAVINGS BANK ANNOUNCES INCREASED EARNINGS
Next Article:AMERICAN/SOVIET EXPEDITION CAPTURES UNPRECEDENTED FOOTAGE OF LUXURY LINER IN AL GIDDINGS' 'TITANIC -- TREASURE OF THE DEEP,' MAY 15 ON CBS


Related Articles
XOMA ANNOUNCES FDA REVIEW OF FIRST E5(R) MULTICENTER STUDY COMPLETED AND EUROPEAN PATENT ALLOWABILITY
FDA REVIEW OF XOMA'S E5(R) PRODUCT IS ACTIVE; COMPANY BELIEVES MARKET OVERREACTED
XOMA NAMES CASTELLO PRESIDENT AND CEO, EXPANDS MANAGEMENT TEAM; NEWS CONFERENCE AT 10 A.M. PDT IN SAN FRANCISCO'S PARK HYATT HOTEL
XOMA UPDATES FDA REVIEW STATUS OF E5
XOMA COMMENTS ON FDA REVIEW OF E5
XOMA ANNOUNCES NEW STRATEGIC FOCUS AND RESTRUCTURING
XOMA ANNOUNCES NEW E5 CLINICAL TRIAL
XOMA'S E5 PRODUCT SUBMITTED FOR APPROVAL IN JAPAN
XOMA ANNOUNCES FINANCING
COURT DISMISSES SECURITIES CLAIMS AGAINST XOMA

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters